Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRIPBOT: TNT with Radiotherapy and Pucotenlimab for MSS Rectal Cancer
NCT06872606Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in rectal adenocarcinoma, sponsored by Sir Run-Run Shaw Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06872606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872606.